PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014;129(3):e28-e292
   PubMed Web of Science ®Google Scholar
• Gaglia MA Jr, Clavijo L. Cardiovascular pharmacology core reviews: aspirin. J Cardiovasc Pharmacol Ther 2013;18(6):505-13
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011;58(23):2432-46
   PubMed Web of Science ®Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60
   PubMed Web of Science ®Google Scholar
• Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162(19):2197-202
   PubMedGoogle Scholar
• Duffy D, Kelly E, Trang A, et al. Aspirin for cardioprotection and strategies to improve patient adherence. Postgrad Med 2014;126(1):18-28
   PubMed Web of Science ®Google Scholar
• Mangiapane S, Busse R. Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis. Dtsch Arztebl Int 2011;108(50):856-62
   PubMed Web of Science ®Google Scholar
• Iwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol 2013;19(11):1673-82
   PubMed Web of Science ®Google Scholar
• Cayla G, Collet JP, Silvain J, et al. Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol 2012;156(1):69-75
   PubMed Web of Science ®Google Scholar
• Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 2009;30(8):900-7
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363(10):930-42
   PubMed Web of Science ®Google Scholar
• Hall HM, de Lemos JA, Enriquez JR, et al. Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the united states: results from the national cardiovascular data registry (NCDR). Circ Cardiovasc Qual Outcomes 2014;7(5):701-7
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52(18):1502-17
   PubMed Web of Science ®Google Scholar
• Hirata Y, Kataoka H, Shimura T, et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol 2011;46(7-8):803-9
   PubMed Web of Science ®Google Scholar
• Sylvester KW, Cheng JW, Mehra MR. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag 2013;9:245-54
   PubMedGoogle Scholar
• Hedberg J, Sundstrom J, Thuresson M, et al. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding–a cohort study of the effects of proton pump inhibitor use patterns. J Intern Med 2013;274(4):371-80
   PubMed Web of Science ®Google Scholar
• de Jong HJ, Korevaar JC, van Dijk L, et al. Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open 2013;3(7):e003044
   PubMed Web of Science ®Google Scholar
• Bytzer P, Pratt S, Elkin E, et al. Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study. Am J Cardiovasc Drugs 2013;13(1):27-35
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713-19
   PubMed Web of Science ®Google Scholar
• Bryant L, Martini N, Chan J, et al. Could the polypill improve adherence? The patient perspective. J Prim Health Care 2013;5(1):28-35
   PubMedGoogle Scholar
• GlaxoSmithKline. Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions: ClinicalTrials.gov. 2013. updated December 5, 2013; cited 2014. Available from: www.clinicaltrials.gov/ct2/show/NCT01847404?term=aspirin+pantoprazole&rank=1
   Google Scholar
• Food and Drug Administration US. NDA 21-849 Prior Approval Supplement 1.14.1.3 Draft Labeling Text. 2007. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021849Orig1s002.pdf
   Google Scholar
• Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988;95(2):289-94
   PubMed Web of Science ®Google Scholar
• Alberts Mark J, Fort JG, Orlemans E, et al. editors. Efficacy and safety of PA, a novel combination of enteric-coated aspirin and immediate-release omeprazole. International Stroke Conference; San Diego, CA. 2009
   Google Scholar
• Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115(25):3156-64
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008;118(17):1705-12
   PubMed Web of Science ®Google Scholar
• Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. Aliment Pharmacol Ther 2013;38(1):62-71
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009;65(1):19-31
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Smith ZL, Fort JG, Zhang Y. Prevalence of gastric ulcers in aspirin users and does the presence of erosions foreshadow ulcer development. Digestive Disease Week, Orlando, FL, 2013; abstract
   Google Scholar
• Whellan D, Goldstein JL, Cryer BL, et al. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin associated gastric ulcers: results of two, 6-month, phase 3 studies. Am Heart J 2014; In Press
   Web of Science ®Google Scholar
• Arbel Y, Birati EY, Finkelstein A, et al. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Clin Cardiol 2013;36(6):342-6
   PubMed Web of Science ®Google Scholar
• Ho CW, Tse YK, Wu B, et al. The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study. Aliment Pharmacol Ther 2013;37(8):819-24
   PubMed Web of Science ®Google Scholar
• Dunn SP, Steinhubl SR, Bauer D, et al. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2013;2(1):e004564
   Web of Science ®Google Scholar
• Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors–where do we stand in 2012? World J Gastroenterol 2012;18(18):2161-71
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363(20):1909-17
   PubMed Web of Science ®Google Scholar
• Lettino M. Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies? Eur J Intern Med 2010;21(6):484-9
   PubMed Web of Science ®Google Scholar
• Tsantes AE, Ikonomidis I, Papadakis I, et al. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Thromb Res 2013;132(2):e105-11
   Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Fort J, et al. Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study. Clin Pharmacol Ther 2011;90(6):860-6
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Fort JG, et al. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. Am Heart J 2013;165(2):176-82
   PubMed Web of Science ®Google Scholar
• Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310(9):918-29
   PubMed Web of Science ®Google Scholar
• Tang XF, Fan JY, Meng J, et al. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis 2014;233(2):568-78
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, D’Ascenzo F, Tomek A, et al. Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. Int J Cardiol 2013;168(3):1739-44
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Windecker S. Antiplatelet therapy for secondary prevention of coronary artery disease. Heart 2014. [Epub ahead of print]
   Google Scholar
• Cooper RS, Layden J. Populations and polypills: if yes, then how? J Epidemiol Community Health 2013;67(11):903-4
   PubMed Web of Science ®Google Scholar
• Holmes MV, Bhala N. The physiological paradox: reframing the polypill as a vaccine for cardiovascular disease. J Epidemiol Community Health 2013;67(11):897-902
   PubMed Web of Science ®Google Scholar